About acumen pharmaceuticals inc - ABOS
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Newton, MA.
ABOS At a Glance
Acumen Pharmaceuticals, Inc.
1210-1220 Washington Street
Newton, Massachusetts 02465
| Phone | 1-617-344-4190 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -121,335,000.00 | |
| Sector | Health Technology | Employees | 61 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ABOS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.815 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.342 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.741 |
ABOS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,989,098.361 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ABOS Liquidity
| Current Ratio | 4.074 |
| Quick Ratio | 4.074 |
| Cash Ratio | 3.895 |
ABOS Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -67.038 |
| Return on Equity | -96.204 |
| Return on Total Capital | -119.259 |
| Return on Invested Capital | -79.77 |
ABOS Capital Structure
| Total Debt to Total Equity | 44.457 |
| Total Debt to Total Capital | 30.775 |
| Total Debt to Total Assets | 25.457 |
| Long-Term Debt to Equity | 31.799 |
| Long-Term Debt to Total Capital | 22.013 |